Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus Fluzoparib in HRD-positive HR+/HER2- advanced breast cancer
NCT06254066Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab, fluzoparib in breast cancer, sponsored by Zhejiang Cancer Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
adebrelimabfluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06254066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254066.